Giuseppe Michieli
#Breakthrough #SARS-CoV-2 #Infections in the PROVENT #Prevention Trial Were Not Associated with AZD7442 (#Tixagevimab/Cilgavimab) Resistant Variants https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad210/7191107?rss=1
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated with AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants

AbstractBackground. We report spike protein-based lineage and AZD7442 (tixagevimab/cilgavimab) neutralizing activity of SARS-CoV-2 variants identified from brea

OUP Academic
Jun 7, 2023 at 8:54amWeb
Show threadGiuseppe MichieliJun 7, 2023
''Symptomatic COVID-19 breakthrough cases in PROVENT were not due to resistance-associated substitutions in AZD7442 binding sites or lack of AZD7442 exposure.''